


MEDICINAL PRODUCTS 2018



Foamix Pharmaceuticals Ltd. Rank 31 of 49





MEDICINAL PRODUCTS 2018



Foamix Pharmaceuticals Ltd. Rank 31 of 49

The relative strengths and weaknesses of Foamix Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foamix Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 154% points. The greatest weakness of Foamix Pharmaceuticals Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is -16%, being 5.5% points above the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	69,504
Assets, Non-Current	10,750
General and Administrative Expense	11,504
Goodwill	0
Liabilities, Current	10,228
Liabilities, Non-Current	1,425
Other Assets	-2,042
Other Compr. Net Income	0
Other Expenses	1,164
Other Liabilities	0
Other Net Income	1,063
Other Revenues	3,669
Property, Plant and Equipment, Net	2,042
Research and Development	57,779

Output Variable	Value in 1000 USD
Liabilities	11,653
Assets	80,254
Expenses	70,447
Revenues	3,669
Stockholders Equity	68,601
Net Income	-65,715
Comprehensive Net Income	-65,715
Economic Capital Ratio	-16%

